In a review of the scientific evidence about sexual dysfunction caused by antidepressants, Australian researchers determined that some of the medications are worse than others.
Publishing in Australasian Psychiatry, the authors noted that, “Antidepressant-induced sexual dysfunction is a common, troublesome complication of antidepressant treatment that patients often fail to report, which can have major consequences.”
After reviewing the literature on the topic, the authors concluded that, “The preponderance of evidence suggests that antidepressants can be divided into high risk (selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, tricyclic antidepressants, monoamine oxidase inhibitors) and low risk (agomelatine, bupropion, moclobemide and reboxetine) categories with regard to propensity for antidepressant-induced sexual dysfunction, although there is disagreement, particularly about mirtazapine, and methodological issues militate against definitive findings.”
They also stated that antidepressant-induced sexual dysfunction is somewhat “dose-dependent”, and that there seemed to be significant differences in how the drugs affected men compared to women. They did not provide specific rates of sexual dysfunction among users of the drugs.
“It is important to ask antidepressant-treated patients about sexual dysfunction as few self-report; this may well contribute to antidepressant non-adherence.”
(Abstract) Management of antidepressant-induced sexual dysfunction (Keks, Nicholas et al. Australasian Psychiatry. December 2014. doi: 10.1177/1039856214556323)